BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Volokhina EB, Westra D, van der Velden TJ, van de Kar NC, Mollnes TE, van den Heuvel LP. Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission. Clin Exp Immunol 2015;181:306-13. [PMID: 25079699 DOI: 10.1111/cei.12426] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Volokhina E, Wijnsma K, van der Molen R, Roeleveld N, van der Velden T, Goertz J, Sweep F, Brüggemann R, Wetzels J, van de Kar N, van den Heuvel L. Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment. Clin Pharmacol Ther 2017;102:671-8. [DOI: 10.1002/cpt.686] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
2 Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol 2018;102:89-119. [PMID: 30121124 DOI: 10.1016/j.molimm.2018.06.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
3 Cugno M, Tedeschi S, Ardissino G. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment. J Thromb Haemost 2015;13:485-6. [PMID: 25345369 DOI: 10.1111/jth.12764] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
4 Puraswani M, Khandelwal P, Saini H, Saini S, Gurjar BS, Sinha A, Shende RP, Maiti TK, Singh AK, Kanga U, Ali U, Agarwal I, Anand K, Prasad N, Rajendran P, Sinha R, Vasudevan A, Saxena A, Agarwal S, Hari P, Sahu A, Rath S, Bagga A. Clinical and Immunological Profile of Anti-factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database. Front Immunol 2019;10:1282. [PMID: 31231391 DOI: 10.3389/fimmu.2019.01282] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Raina R, Sethi SK, Dragon-Durey MA, Khooblall A, Sharma D, Khandelwal P, Shapiro R, Boyer O, Yap HK, Bagga A, Licht C. Systematic review of atypical hemolytic uremic syndrome biomarkers. Pediatr Nephrol 2022. [PMID: 35118546 DOI: 10.1007/s00467-022-05451-2] [Reference Citation Analysis]
6 Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar NCAJ, Wetzels JFM. Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrol Dial Transplant 2018;33:635-45. [PMID: 29106598 DOI: 10.1093/ndt/gfx196] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
7 Berger BE. The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome. Am J Med Sci 2016;352:177-90. [PMID: 27524217 DOI: 10.1016/j.amjms.2016.05.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
8 Blasco M, Guillén E, Quintana LF, Garcia-Herrera A, Piñeiro G, Poch E, Carreras E, Campistol JM, Diaz-Ricart M, Palomo M. Thrombotic microangiopathies assessment: mind the complement. Clin Kidney J 2021;14:1055-66. [PMID: 33841853 DOI: 10.1093/ckj/sfaa195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Farkas P, Csuka D, Mikes B, Sinkovits G, Réti M, Németh E, Rácz K, Madách K, Gergely M, Demeter J, Prohászka Z. Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies. Immunobiology 2017;222:119-27. [DOI: 10.1016/j.imbio.2016.10.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
10 Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of Atypical Hemolytic Uremic Syndrome. J Atheroscler Thromb 2019;26:99-110. [PMID: 30393246 DOI: 10.5551/jat.RV17026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
11 de Jong S, de Breuk A, Volokhina EB, Bakker B, Garanto A, Fauser S, Katti S, Hoyng CB, Lechanteur YTE, van den Heuvel LP, den Hollander AI. Systemic complement levels in patients with age-related macular degeneration carrying rare or low frequency variants in the CFH gene. Hum Mol Genet 2021:ddab256. [PMID: 34508573 DOI: 10.1093/hmg/ddab256] [Reference Citation Analysis]
12 Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol 2017;187:304-15. [PMID: 27784126 DOI: 10.1111/cei.12890] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
13 Westra D, Volokhina EB, van der Molen RG, van der Velden TJ, Jeronimus-Klaasen A, Goertz J, Gracchi V, Dorresteijn EM, Bouts AH, Keijzer-Veen MG, van Wijk JA, Bakker JA, Roos A, van den Heuvel LP, van de Kar NC. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol 2017;32:297-309. [PMID: 27718086 DOI: 10.1007/s00467-016-3496-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
14 Zhang Y, Kremsdorf RA, Sperati CJ, Henriksen KJ, Mori M, Goodfellow RX, Pitcher GR, Benson CL, Borsa NG, Taylor RP, Nester CM, Smith RJH. Mutation of complement factor B causing massive fluid-phase dysregulation of the alternative complement pathway can result in atypical hemolytic uremic syndrome. Kidney Int 2020;98:1265-74. [PMID: 32540405 DOI: 10.1016/j.kint.2020.05.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Riedemann NC, Habel M, Ziereisen J, Hermann M, Schneider C, Wehling C, Kirschfink M, Kentouche K, Guo R. Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition. Clin Immunol 2017;180:25-32. [PMID: 28366510 DOI: 10.1016/j.clim.2017.03.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
16 Michels MAHM, van de Kar NCAJ, van den Bos RM, van der Velden TJAM, van Kraaij SAW, Sarlea SA, Gracchi V, Oosterveld MJS, Volokhina EB, van den Heuvel LPWJ. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy. Front Immunol 2019;10:1350. [PMID: 31263464 DOI: 10.3389/fimmu.2019.01350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
17 Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15-39. [PMID: 25859752 DOI: 10.1007/s00467-015-3076-8] [Cited by in Crossref: 272] [Cited by in F6Publishing: 210] [Article Influence: 38.9] [Reference Citation Analysis]
18 Schalk G, Kirschfink M, Wehling C, Gastoldi S, Bergmann C, Hoppe B, Weber LT. A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab. Pediatr Nephrol 2015;30:1039-42. [PMID: 25752761 DOI: 10.1007/s00467-015-3078-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
19 Timmermans SAMEG, Abdul-Hamid MA, Vanderlocht J, Damoiseaux JGMC, Reutelingsperger CP, van Paassen P; Limburg Renal Registry. Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. Kidney Int 2017;91:1420-5. [PMID: 28187980 DOI: 10.1016/j.kint.2016.12.009] [Cited by in Crossref: 63] [Cited by in F6Publishing: 50] [Article Influence: 12.6] [Reference Citation Analysis]
20 Michels MAHM, van de Kar NCAJ, Okrój M, Blom AM, van Kraaij SAW, Volokhina EB, van den Heuvel LPWJ. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases. Front Immunol 2018;9:612. [PMID: 29670616 DOI: 10.3389/fimmu.2018.00612] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
21 Arachchillage DRJ, Mackie IJ, Efthymiou M, Chitolie A, Hunt BJ, Isenberg DA, Khamashta M, Machin SJ, Cohen H. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism. J Thromb Haemost 2016;14:2177-86. [DOI: 10.1111/jth.13475] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
22 Abe T, Sasaki A, Ueda T, Miyakawa Y, Ochiai H. Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report. Medicine (Baltimore) 2017;96:e6056. [PMID: 28178155 DOI: 10.1097/MD.0000000000006056] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
23 Bouwmeester RN, Ter Avest M, Wijnsma KL, Duineveld C, Ter Heine R, Volokhina EB, Van Den Heuvel LPWJ, Wetzels JFM, van de Kar NCAJ. Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient. Front Immunol 2020;11:612706. [PMID: 33519821 DOI: 10.3389/fimmu.2020.612706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Yoshida Y, Kato H, Nangaku M. Atypical hemolytic uremic syndrome. Ren Replace Ther 2017;3. [DOI: 10.1186/s41100-016-0088-1] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
25 Michels MAHM, Wijnsma KL, Kurvers RAJ, Westra D, Schreuder MF, van Wijk JAE, Bouts AHM, Gracchi V, Engels FAPT, Keijzer-Veen MG, Dorresteijn EM, Volokhina EB, van den Heuvel LPWJ, van de Kar NCAJ. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort. Pediatr Nephrol 2021. [PMID: 34476601 DOI: 10.1007/s00467-021-05221-6] [Reference Citation Analysis]
26 Bu F, Meyer NC, Zhang Y, Borsa NG, Thomas C, Nester C, Smith RJ. Soluble c5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome. Am J Kidney Dis 2015;65:968-9. [PMID: 25818678 DOI: 10.1053/j.ajkd.2015.02.326] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
27 van den Heuvel L, Riesbeck K, El Tahir O, Gracchi V, Kremlitzka M, Morré SA, van Furth AM, Singh B, Okrój M, van de Kar N, Blom AM, Volokhina E. Genetic predisposition to infection in a case of atypical hemolytic uremic syndrome. J Hum Genet 2018;63:93-6. [PMID: 29215086 DOI: 10.1038/s10038-017-0356-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
28 Mannucci P, Cugno M. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. Thrombosis Research 2015;136:851-4. [DOI: 10.1016/j.thromres.2015.09.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]